In pancreatic cancer, combined chemo-immunotherapy with anti-MUC16 led to the development of specific T-cell immunity [19] while targeting MUC16 revealed prolonged progression-free and OS in a Phase II study in advanced ovarian cancer [30]. The gene discussed is MUC16; the disease is familial pancreatic carcinoma.